Mittie Doyle
Chief Medical OfficerDr. Mittie Doyle, M.D., FACR, is Chief Medical Officer of Avalo Therapeutics, Inc. from July 2024. Dr. Doyle joined the Avalo Therapeutics, Inc. in July 2024. She is Director at Cullinan Therapeutics, Inc. since August 7, 2025. She served as Director of DICE Therapeutics, Inc. since March 2022 until August 2023. She serves as Director at Santa Ana Bio, Inc. She served as Vice President of Clinical Research at Flexion Therapeutics, Inc., until August 04, 2016. She served as Chief Medical Officer at Aro Biotherapeutics Company since September 2021 until July, 2024. She served as a Vice President of R&D Immunology - CSL Behring at CSL Limited. Dr. Doyle held senior level roles at Shire Pharmaceuticals. Dr. Doyle has many years of clinical, academic and biopharmaceutical experience. Prior to joining Flexion, she served as Senior Medical Director in Translational Medicine at Alexion Pharmaceuticals focusing on First in Human and Proof of Concept studies in orphan diseases. Prior to her tenure at Alexion, Dr. Doyle held positions of increasing responsibility at Centocor and Janssen R&D where she worked on the successful BLA filing for Golimumab in Rheumatoid Arthritis and served as Clinical lead for the Phase III Ustekinumab Psoriatic arthritis program. She has held faculty positions at Harvard Medical School, Tulane University School of Medicine and the University of Pennsylvania School of Medicine. Following an internship and residency in Internal Medicine at Massachusetts General Hospital, Dr. Doyle completed clinical and research fellowships in Rheumatology and Immunology at Brigham and Women’s Hospital and Harvard Medical School. She is Board certified in Rheumatology and maintains a clinical practice at the Veterans Administration Hospital. Dr. Doyle served as Vice President, Global Therapeutic Area Head, Research & Development, Immunology at CSL Behring from October 2017 to October 2021, as Vice President, Global Development Lead of Shire Pharmaceuticals from August 2016 to October 2017, as Vice President, Clinical Research of Flexion Therapeutics from April 2015 to August 2016 and as Senior Medical Director of Alexion Pharmaceuticals from June 2012 to April 2015. Dr. Doyle earned her BA in Romance Languages magna cum laude, from Princeton University and her MD, cum laude, from Yale University School of Medicine.
Positions
- Company NameAvalo Therapeutics, Inc.Stock CodeAVTXPositionChief Medical OfficerColleagues
- GAGarry A. NeilPresident, CEO & Director
- MTMichael Thomas HeffernanIndependent Chairman of the Board
- TBTaylor BoydChief Business Officer
- SHSolomon H. SnyderFounder and Chairman of Scientific Advisory Board
- BSBarbara S. SlusherFounder and Member of Scientific Advisory Board
- SSSamantha Scollard TruexIndependent Director
